By Counterforce Health Team in Elelyso (taliglucerase alfa) —

How to Get Elelyso (Taliglucerase Alfa) Covered by Aetna (CVS Health) in New Jersey: Appeals Guide with Forms and Timelines

Quick Answer: Getting Elelyso Covered by Aetna (CVS Health) in New Jersey

Elelyso (taliglucerase alfa) requires prior authorization from Aetna (CVS Health) and typically faces step therapy requirements favoring Cerezyme or VPRIV first. If denied, you have strong appeal rights in New Jersey through internal reviews and the state's Independent Health Care Appeals Program (IHCAP) via Maximus Federal Services. Start today by: 1) Requesting prior authorization with documented Gaucher disease diagnosis and treatment history, 2) If denied, file internal appeal within 180 days, 3) Use New Jersey's external review if needed—decisions are binding and favor patients in ~50% of cases.

Table of Contents

  1. Understanding Your Denial Letter
  2. Aetna Coverage Requirements for Elelyso
  3. Step-by-Step: Fastest Path to Approval
  4. Common Denial Reasons & How to Fix Them
  5. Medical Necessity Letter Template
  6. Appeals Process in New Jersey
  7. External Review Through IHCAP
  8. Peer-to-Peer Review Strategy
  9. Patient Support and Cost Assistance
  10. When to Escalate to Regulators
  11. FAQ

Understanding Your Denial Letter

When Aetna (CVS Health) denies Elelyso, the letter will specify the denial reason and your appeal rights. Look for these key elements:

  • Denial basis: Step therapy required, non-formulary status, or "not medically necessary"
  • Appeal deadline: Typically 180 days from the denial date for internal appeals
  • Required documentation: What additional information Aetna needs
  • Reference number: Essential for all follow-up communications
Tip: Take a photo of the denial letter immediately—you'll reference it throughout the appeal process.

Aetna Coverage Requirements for Elelyso

Based on Aetna's precertification requirements, Elelyso faces these coverage hurdles:

Requirement Details How to Address
Prior Authorization Mandatory for all specialty biologics Submit via Aetna provider portal
Step Therapy Must try Cerezyme or VPRIV first Document failure, intolerance, or contraindication
Specialist Prescriber Hematologist, geneticist, or metabolic specialist Ensure prescriber credentials are clear
Confirmed Diagnosis Type 1 Gaucher disease with enzyme/genetic testing Include lab results and ICD-10 code E75.22
Appropriate Dosing 60 units/kg IV every 2 weeks per FDA label Match prescription to approved dosing

Step-by-Step: Fastest Path to Approval

  1. Gather Documentation (Patient/Clinic)
    • Enzyme assay showing β-glucocerebrosidase deficiency
    • Genetic testing confirming GBA1 mutations
    • Clinical notes documenting symptoms (anemia, organomegaly, bone issues)
    • Timeline: Same day
  2. Submit Prior Authorization (Prescriber)
  3. Document Step Therapy Exception (Prescriber)
    • Provide evidence of Cerezyme/VPRIV failure or contraindication
    • Include adverse event reports or treatment history
    • Timeline: Include with initial PA
  4. Await Decision (Patient)
    • Standard review: 30-45 days
    • Expedited review: 72 hours if urgent
    • Track via Aetna provider portal
  5. File Internal Appeal if Denied (Patient/Prescriber)
    • Submit within 180 days of denial
    • Include comprehensive medical necessity letter
    • Timeline: 30 days for standard appeal decision
  6. Request Peer-to-Peer Review (Prescriber)
    • Schedule within 14 days of denial
    • Direct discussion with Aetna medical director
    • Timeline: 1 business day to schedule
  7. External Review via IHCAP (Patient)
    • File within 4 months if internal appeals fail
    • Binding decision through Maximus Federal Services
    • Timeline: 45 days for decision

Common Denial Reasons & How to Fix Them

Denial Reason Solution Strategy Required Documentation
Step therapy not met Document prior ERT failure/intolerance Treatment records, adverse event notes, specialist letter
Not medically necessary Strengthen clinical justification Updated labs, symptom progression, functional impact
Non-formulary drug Request formulary exception Comparative effectiveness data, contraindications to alternatives
Experimental/investigational Cite FDA approval and guidelines FDA label, published treatment guidelines
Incorrect diagnosis code Verify ICD-10 coding Use E75.22 for Type 1 Gaucher disease

Medical Necessity Letter Template

Essential Components for Elelyso Appeals:

[Date]
[Aetna Medical Management]
[Address from denial letter]

Re: [Patient Name], DOB: [Date], Member ID: [Number]
Request for: Elelyso (taliglucerase alfa), HCPCS J3060

Dear Medical Director:

DIAGNOSIS: Type 1 Gaucher disease confirmed by [enzyme assay/genetic testing] on [date].

CLINICAL PRESENTATION:
- Anemia: Hemoglobin [value] g/dL (normal 12-15.5)
- Thrombocytopenia: Platelets [value]/µL (normal 150,000-450,000)
- Hepatosplenomegaly: [imaging findings]
- Bone involvement: [pain, crises, or imaging abnormalities]

TREATMENT HISTORY:
[Document prior ERT trials with specific dates, doses, and outcomes]
- Cerezyme (imiglucerase): [dates, response, reason for discontinuation]
- VPRIV (velaglucerase alfa): [dates, response, reason for discontinuation]

RATIONALE FOR ELELYSO:
Patient requires alternative ERT due to [documented intolerance/inadequate response/contraindication] to preferred agents. Elelyso is FDA-approved for this indication and clinically appropriate.

EXPECTED OUTCOMES:
- Improved hemoglobin and platelet counts
- Reduced organomegaly
- Decreased bone pain and complications

PLAN: 60 units/kg IV every 2 weeks with routine monitoring per specialty guidelines.

Respectfully,
[Prescriber name, credentials, NPI]

Appeals Process in New Jersey

New Jersey provides robust appeal rights through multiple levels:

Internal Appeals (Aetna)

  • First level: 180 days to file, 30 days for decision
  • Second level: Available if first level denied
  • Expedited: 72 hours for urgent cases
  • Submit via: Aetna member portal or written request

Required Documentation

  • Copy of denial letter
  • Medical necessity letter from prescriber
  • Supporting clinical records
  • Patient consent for provider to file on their behalf
Note: New Jersey requires insurers to provide clear appeal instructions and cannot deny appeals for minor procedural errors.

External Review Through IHCAP

If Aetna denies your internal appeals, New Jersey's Independent Health Care Appeals Program offers binding external review:

Key Details

  • Administered by: Maximus Federal Services
  • Filing deadline: 4 months from final internal denial
  • Decision timeline: 45 days (48 hours for expedited)
  • Cost: Free to patients
  • Success rate: Approximately 50% favor patients nationwide

Contact Information

Filing Requirements

  • Final adverse determination letter from Aetna
  • Completed IHCAP external appeal form
  • Supporting medical documentation
  • Statement of urgency (if requesting expedited review)

Peer-to-Peer Review Strategy

Before or during appeals, request a peer-to-peer call between your prescriber and an Aetna medical director:

Preparation Checklist

  • Patient's complete medical history
  • Diagnostic test results
  • Prior treatment timeline and outcomes
  • Published guidelines supporting Elelyso use
  • Specific reasons other ERTs are inappropriate

Scheduling

  • Request within 14 days of denial
  • Use number provided in denial letter
  • Aetna must respond within 1 business day to schedule

At Counterforce Health, we help patients and providers navigate complex insurance denials by turning rejection letters into targeted, evidence-backed appeals. Our platform analyzes denial reasons and drafts point-by-point rebuttals aligned with each plan's specific policies, saving time and improving approval rates.

Patient Support and Cost Assistance

While pursuing coverage, explore these support options:

Manufacturer Programs

  • Pfizer Gaucher Personal Support (GPS): Coverage navigation and copay assistance
  • Eligibility: Varies by insurance type and income
  • Services: Prior authorization support, appeals assistance, financial aid

Foundation Support

  • National Gaucher Foundation
  • Patient Access Network Foundation
  • Various rare disease foundations offering grants
From our advocates: "One family found success by combining a strong medical necessity letter with documentation from three prior ERT failures. The key was showing not just that other treatments didn't work, but specifically how Elelyso addressed the patient's unique clinical situation. Their external review was approved within 30 days."

When to Escalate to Regulators

If standard appeals fail or you encounter procedural violations, contact:

New Jersey Department of Banking and Insurance

  • Consumer Hotline: 1-800-446-7467
  • IHCAP Support: 1-888-393-1062
  • Website: nj.gov/dobi
  • File complaints for: Improper denial procedures, missed deadlines, failure to provide required information

When to File Complaints

  • Aetna misses appeal deadlines
  • Denial letter lacks required information
  • Peer-to-peer review improperly denied
  • External review rights not explained

FAQ

How long does Aetna prior authorization take for Elelyso in New Jersey? Standard review takes 30-45 days, with over 95% of eligible requests processed within 24 hours. Expedited reviews for urgent cases are completed within 72 hours.

What if Elelyso is non-formulary on my Aetna plan? Request a formulary exception by demonstrating medical necessity and inadequate alternatives. Include documentation of prior treatment failures and specialist support.

Can I request an expedited appeal if I'm already on Elelyso? Yes, if discontinuing treatment would cause serious harm to your health. Provide physician certification of urgency with your appeal.

Does step therapy apply if I failed other ERTs outside New Jersey? Treatment history from other states counts toward step therapy requirements. Include complete medical records and prescriber attestation of prior failures.

What happens if my external review is approved? Aetna must comply with the binding decision and provide coverage. The insurer cannot appeal the external review determination.

How much does Elelyso cost without insurance? The wholesale acquisition cost ranges from approximately $839-$899 per 200-unit vial, with typical patients requiring multiple vials per infusion based on weight and dosing.

Can my doctor file appeals on my behalf? Yes, with your written consent. Many specialists prefer to handle appeals directly given their familiarity with clinical justification requirements.

What if I have Medicare Advantage through Aetna? Medicare Advantage follows different federal appeal timelines and may have additional external review options through Medicare's Independent Review Entity (IRE).

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and medical circumstances. Always consult with your healthcare provider and insurance plan for specific guidance. For additional support with insurance appeals, visit www.CounterforceHealth.org to learn how we help patients navigate coverage denials.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.